市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (AU) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | DIMERIX FPO [DXB] | - | - |
AIStockmoo 评分
-0.3
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -1.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -2.5 |
| 平均 | -0.33 |
|
Dimerix Ltd is a biopharmaceutical company developing new therapies in areas with unmet medical needs. The company is developing four product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for COPD, as well as the proprietary ReceptorHIT assay technology. It pursues new product concepts and applies deep scientific knowledge to the discovery of products from early-stage development through to commercialisation. Dimerix products will target multiple territories. The Group has only operated in one Segment, being investment in research and development of biopharmaceutical drugs. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 23.75% |
| 机构持股比例 | 1.54% |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合